How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/light-chain-al-amyloidosis-in-combination-with-bortezomib-cyclophosphamide-and-dexamethasone-in-newly-diagnosed-patients.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Darzalex Faspro	daratumumab-and-hyaluronidase-fihj	Pfizer	CD38-directed Cytolytic Antibody [EPC]	CD38		2020-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 1 drug in Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients:

Cite this brief

Drug Landscape (2026). Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/light-chain-al-amyloidosis-in-combination-with-bortezomib-cyclophosphamide-and-dexamethasone-in-newly-diagnosed-patients. Accessed 2026-06-10.

Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing